A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.
Financial Summary
| Share Statistics | ZLDPY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3,235.8 | $282.4 | 60% |
|
| Shares Out (Mil) | 10.8 | 54.0 | 21% |
|
| Institutional Ownership | 49.1% | 93.1% | 23% |
|
| Float (Mil) | 54.2 | 42.2 | 49% |
|
| Beta | 0.60 | 0.94 | 35% |
|
| Avg Daily Volume (000s) | 1 | 482 | 4% |
|
| Price Change (52-week) |
na | 59.9% | na |
|
| Growth | ZLDPY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 114.9% | 14.1% | 99% |
|
| Net Income (5yr) | 56.2% | (10.1%) | 95% |
|
| EPS (5yr) | 42.7% | 15.9% | 90 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 80.8% | (15.6%) | 97% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | ZLDPY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $710 | $37 | 45% |
|
| Net Income (TTM) (Mil) | $419 | ($43) | 76% |
|
| EPS (TTM) | $5.950 | ($1.500) | 89% |
|
| Operating Cash Flow (TTM) (Mil) | ($268) | ($31) | 3% |
|
| Net Cash Flow (TTM) (Mil) | ($503) | $2 | 6% |
|
| Long-Term Debt (Q1) (Mil) | $58 | $4 | 40% |
|
| Enterprise Value (Q1) (Mil) | $1,469 | $190 | 45% |
|
| Valuation | ZLDPY | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.84 | na |
|
| P/E | na | 20.2 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | ZLDPY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 66.9% | 96% |
|
| Net Margin | 59.0% | (74.2%) | 98% |
|
| ROA | 14.6% | (47.7%) | 93% |
|
| ROE | 16.1% | (55.0%) | 73% |
|
| Liabilities to Assets | 8.9% | 29.8% | 5% |
|
| F-Score | na | 3 | na |
|
Zealand Pharma A/S did not pass any screens on 9/4/2026.
